乳腺癌的内分泌治疗新进展  

Endocrine Therapy of Breast Cancer

作　　者：王昕怡[1] 张珍[2] 邵加庆[1] 

机构地区：[1]南京大学医学院临床学院,南京军区南京总医院内分泌科,江苏省南京市210002 [2]南方医科大学南京临床学院

出　　处：《中国全科医学》2012年第9期959-962,共4页Chinese General Practice

基　　金：国家自然科学基金资助项目(30900697);江苏省"六大人才高峰"培养对象项目(2008060)

摘　　要：乳腺癌是激素依赖性肿瘤,雌激素的长期刺激对乳腺癌的发生具有重要作用。对雌激素受体(ER)和(或)孕激素受体(PR)阳性的乳腺癌患者,术后都应该接受辅助内分泌治疗。应根据患者的具体情况个体化选用内分泌治疗方法,提高其作为乳腺癌术后辅助治疗和复发转移性乳腺癌解救治疗的疗效。本文将对绝经前、绝经后乳腺癌以及特殊情况下如复发转移性乳腺癌、男性乳腺癌的内分泌治疗进行综述,探讨内分泌治疗抵抗机制的最新进展。Breast cancer is a hormone - dependent tumor in which oestrogen stimulus plays an important role in its oc- currence. For breast cancer patients whose ER and PR are positive, endocrine therapy should be adopted after opera- tion. Endocrine therapy should be applied in accordance with the patients＇ specific conditions to improve its efficacy as an adjuvant therapy and saving treatment for recurrent metastatic breast cancer. This paper summarizes the endocrine therapy for premenopausalbreast cancer, postmenopausal breast cancer and breast cancer in special cases like recurrent metastatic breast cancer and male breast cancer, and discusses the recent advances of resistance to endocrine therapy.

关 键 词：乳腺肿瘤 内分泌治疗 受体 雌激素 

分 类 号：R737.9[医药卫生—肿瘤]